Combination therapy of transcatheter arterial chemoembolization with axitinib for the treatment of inoperable hepatocellular carcinoma

por Nouso, Kazuhiro, Wakuta, Akiko, Kariyama, Kazuya
Publicado 2020

Role of hepatic resection in patients with intermediate‐stage hepatocellular carcinoma: A multicenter study from Japan

por Tada, Toshifumi, Kumada, Takashi, Toyoda, Hidenori, Tsuji, Kunihiko, Hiraoka, Atsushi, Itobayashi, Ei, Nouso, Kazuhiro, Kariyama, Kazuya, Ishikawa, Toru, Hirooka, Masashi, Hiasa, Yoichi
Publicado 2017

Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma

por Kariyama, Kazuya, Nouso, Kazuhiro, Toyoda, Hidenori, Tada, Toshifumi, Hiraoka, Atsushi, Tsuji, Kunihiko, Itobayashi, Ei, Ishikawa, Toru, Wakuta, Akiko, Oonishi, Ayano, Kumada, Takashi, Kudo, Masatoshi
Publicado 2019

Attempt to Establish Prognostic Predictive System for Hepatocellular Carcinoma Using Artificial Intelligence for Assistance with Selection of Treatment Modality

por Hiraoka, Atsushi, Kumada, Takashi, Tada, Toshifumi, Toyoda, Hidenori, Kariyama, Kazuya, Hatanaka, Takeshi, Kakizaki, Satoru, Naganuma, Atsushi, Itobayashi, Ei, Tsuji, Kunihiko, Ishikawa, Toru, Ohama, Hideko, Tada, Fujimasa, Nouso, Kazuhiro
Publicado 2023

The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab

por Takeuchi, Yasuto, Nouso, Kazuhiro, Fujioka, Shin‐ichi, Kariyama, Kazuya, Kobashi, Haruhiko, Uematsu, Shuji, Moriya, Akio, Hagihara, Hiroaki, Takabatake, Hiroyuki, Nakamura, Shinichiro, Yabushita, Kazuhisa, Kikuchi, Tatsuya, Oyama, Atsushi, Adachi, Takuya, Wada, Nozomu, Onishi, Hideki, Shiraha, Hidenori, Takaki, Akinobu
Publicado 2023

Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis

por Hiraoka, Atsushi, Kumada, Takashi, Kariyama, Kazuya, Takaguchi, Koichi, Atsukawa, Masanori, Itobayashi, Ei, Tsuji, Kunihiko, Tajiri, Kazuto, Hirooka, Masashi, Shimada, Noritomo, Shibata, Hiroshi, Ishikawa, Toru, Ochi, Hironori, Tada, Toshifumi, Toyoda, Hidenori, Nouso, Kazuhiro, Tsutsui, Akemi, Itokawa, Norio, Imai, Michitaka, Joko, Kouji, Hiasa, Yoichi, Michitaka, Kojiro
Publicado 2018

Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study

por Izumi, Namiki, Asahina, Yasuhiro, Kurosaki, Masayuki, Yamada, Gotaro, Kawai, Tsutomu, Kajiwara, Eiji, Okamura, Yukishige, Takeuchi, Takayuki, Yokosuka, Osamu, Kariyama, Kazuya, Toyoda, Joji, Inao, Mie, Tanaka, Eiji, Moriwaki, Hisataka, Adachi, Hiroshi, Katsushima, Shinji, Kudo, Masatoshi, Takaguchi, Kouichi, Hiasa, Yoichi, Chayama, Kazuaki, Yatsuhashi, Hiroshi, Oketani, Makoto, Kumada, Hiromitsu
Publicado 2012

The prognosis of elderly patients with hepatocellular carcinoma: A multi‐center 19‐year experience in Japan

por Hatanaka, Takeshi, Kakizaki, Satoru, Hiraoka, Atsushi, Kariyama, Kazuya, Tsuji, Kunihiko, Ishikawa, Toru, Toyoda, Hidenori, Yasuda, Satoshi, Naganuma, Atsushi, Tada, Toshifumi, Takaguchi, Koichi, Tsutsui, Akemi, Itobayashi, Ei, Shimada, Noritomo, Shibata, Hiroshi, Tanaka, Takaaki, Nagano, Takuya, Imai, Michitaka, Nakamura, Shinichiro, Nouso, Kazuhiro, Kosaka, Hisashi, Kaibori, Masaki, Kumada, Takashi
Publicado 2022

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis

por Hiraoka, Atsushi, Kumada, Takashi, Atsukawa, Masanori, Hirooka, Masashi, Tsuji, Kunihiko, Ishikawa, Toru, Takaguchi, Koichi, Kariyama, Kazuya, Itobayashi, Ei, Tajiri, Kazuto, Shimada, Noritomo, Shibata, Hiroshi, Ochi, Hironori, Tada, Toshifumi, Toyoda, Hidenori, Nouso, Kazuhiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Hayama, Korenobu, Imai, Michitaka, Joko, Kouji, Koizumi, Yohei, Hiasa, Yoichi, Michitaka, Kojiro, Kudo, Masatoshi
Publicado 2019

Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study

por Tada, Toshifumi, Kumada, Takashi, Okushin, Hiroaki, Tani, Joji, Takaguchi, Koichi, Tsutsui, Akemi, Toyoda, Hidenori, Yasuda, Satoshi, Dohmen, Kazufumi, Hiraoka, Atsushi, Michitaka, Kojiro, Nouso, Kazuhiro, Kariyama, Kazuya, Kim, Soo Ryang, Kim, Soo Ki, Fujioka, Shinichi, Mikami, Shigeru, Watanabe, Yuto, Tamai, Tsutomu, Atsukawa, Masanori, Itokawa, Norio, Tanaka, Hironori, Tsuji, Kunihiko, Ishikawa, Toru, Imai, Michitaka, Itobayashi, Ei, Shibata, Hiroshi, Shimada, Noritomo
Publicado 2020

Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab

por Nouso, Kazuhiro, Shiota, Shohei, Fujita, Rio, Wakuta, Akiko, Kariyama, Kazuya, Hiraoka, Atsushi, Atsukawa, Masanori, Tani, Joji, Tada, Toshifumi, Nakamura, Shinichiro, Tajiri, Kazuto, Kaibori, Masaki, Hirooka, Masashi, Itobayashi, Ei, Kakizaki, Satoru, Naganuma, Atsushi, Ishikawa, Toru, Hatanaka, Takeshi, Fukunishi, Shinya, Tsuji, Kunihiko, Kawata, Kazuhito, Takaguchi, Koichi, Tsutsui, Akemi, Ogawa, Chikara, Ochi, Hironori, Yata, Yutaka, Kuroda, Hidekatsu, Iijima, Hiroko, Matono, Tomomitsu, Shimada, Noritomo, Yasuda, Satoshi, Toyoda, Hidenori, Kumada, Takashi
Publicado 2023

Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma

por Hiraoka, Atsushi, Kumada, Takashi, Tada, Toshifumi, Ogawa, Chikara, Tani, Joji, Fukunishi, Shinya, Atsukawa, Masanori, Hirooka, Masashi, Tsuji, Kunihiko, Ishikawa, Toru, Takaguchi, Koichi, Kariyama, Kazuya, Itobayashi, Ei, Tajiri, Kazuto, Shimada, Noritomo, Shibata, Hiroshi, Ochi, Hironori, Kawata, Kazuhito, Toyoda, Hidenori, Ohama, Hideko, Nouso, Kazuhiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Hayama, Korenobu, Arai, Taeang, Imai, Michitaka, Koizumi, Yohei, Nakamura, Shinichiro, Michitaka, Kojiro, Hiasa, Yoichi, Kudo, Masatoshi
Publicado 2020

Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib

por Tada, Toshifumi, Kumada, Takashi, Hiraoka, Atsushi, Atsukawa, Masanori, Hirooka, Masashi, Tsuji, Kunihiko, Ishikawa, Toru, Takaguchi, Koichi, Kariyama, Kazuya, Itobayashi, Ei, Tajiri, Kazuto, Shimada, Noritomo, Shibata, Hiroshi, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Fukunishi, Shinya, Ohama, Hideko, Kawata, Kazuhito, Tani, Joji, Nakamura, Shinichiro, Nouso, Kazuhiro, Tsutsui, Akemi, Nagano, Takuya, Takaaki, Tanaka, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Joko, Kouji, Koizumi, Yohei, Hiasa, Yoichi
Publicado 2021

Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting

por Hiraoka, Atsushi, Kumada, Takashi, Kariyama, Kazuya, Tada, Toshifumi, Tani, Joji, Fukunishi, Shinya, Atsukawa, Masanori, Hirooka, Masashi, Tsuji, Kunihiko, Ishikawa, Toru, Takaguchi, Koichi, Itobayashi, Ei, Tajiri, Kazuto, Shimada, Noritomo, Shibata, Hiroshi, Ochi, Hironori, Kawata, Kazuhito, Yasuda, Satoshi, Toyoda, Hidenori, Ohama, Hideko, Nouso, Kazuhiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Hayama, Korenobu, Arai, Taeang, Imai, Michitaka, Koizumi, Yohei, Nakamura, Shinichiro, Joko, Kouji, Michitaka, Kojiro, Hiasa, Yoichi, Kudo, Masatoshi
Publicado 2020

Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study

por Hiraoka, Atsushi, Kumada, Takashi, Tada, Toshifumi, Tani, Joji, Kariyama, Kazuya, Fukunishi, Shinya, Atsukawa, Masanori, Hirooka, Masashi, Tsuji, Kunihiko, Ishikawa, Toru, Takaguchi, Koichi, Itobayashi, Ei, Tajiri, Kazuto, Shimada, Noritomo, Shibata, Hiroshi, Ochi, Hironori, Kawata, Kazuhito, Yasuda, Satoshi, Toyoda, Hidenori, Aoki, Tomoko, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Arai, Taeang, Okubo, Tomomi, Imai, Michitaka, Koizumi, Yohei, Nakamura, Shinichiro, Joko, Koji, Hiasa, Yoichi, Kudo, Masatoshi
Publicado 2021

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience

por Hiraoka, Atsushi, Kumada, Takashi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Koizumi, Yohei, Nakamura, Shinichiro, Joko, Kouji, Iijima, Hiroko, Hiasa, Yoichi, Kudo, Masatoshi
Publicado 2021

C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib

por Tada, Toshifumi, Kumada, Takashi, Hiraoka, Atsushi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Naganuma, Atsushi, Aoki, Tomoko, Koizumi, Yohei, Nakamura, Shinichiro, Joko, Kouji, Hiasa, Yoichi, Kudo, Masatoshi
Publicado 2022

New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bev...

por Tada, Toshifumi, Kumada, Takashi, Hiraoka, Atsushi, Kariyama, Kazuya, Tani, Joji, Hirooka, Masashi, Takaguchi, Koichi, Atsukawa, Masanori, Fukunishi, Shinya, Itobayashi, Ei, Tsuji, Kunihiko, Tajiri, Kazuto, Ochi, Hironori, Ishikawa, Toru, Yasuda, Satoshi, Ogawa, Chikara, Toyoda, Hidenori, Hatanaka, Takeshi, Nishimura, Takashi, Kakizaki, Satoru, Kawata, Kazuhito, Shimada, Noritomo, Tada, Fujimasa, Nouso, Kazuhiro, Tsutsui, Akemi, Ohama, Hideko, Morishita, Asahiro, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Kosaka, Hisashi, Imai, Michitaka, Naganuma, Atsushi, Nakamura, Shinichiro, Koizumi, Yohei, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi
Publicado 2022

Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab

por Tada, Toshifumi, Kumada, Takashi, Hiraoka, Atsushi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi
Publicado 2022

Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis

por Tada, Toshifumi, Kumada, Takashi, Hiraoka, Atsushi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Joko, Kouji, Iijima, Hiroko, Hiasa, Yoichi
Publicado 2022